International Medica Foundation Reaches Final Vaccination Milestone in Phase II Clinical Trial for Rotavirus Vaccine

Bookmark and Share

ROCHESTER, Minn.--(BUSINESS WIRE)--Rotavirus is responsible for the deaths of more than 1,500 infants and children daily, mainly in developing countries. To combat this killer of children, the International Medica Foundation is sponsoring a Phase II clinical trial of its oral rotavirus vaccine, RotaShield®.

MORE ON THIS TOPIC